All
Secukinumab approved for psoriatic arthritis and ankylosing spondylitis
February 15th 2016Novartis announced January 15 that the FDA has approved secukinumab (Cosentyx, Novartis) for psoriatic arthritis (PsA) and active ankylosing spondylitis. The announcement comes a year after the FDA’s approval for secukinumab for treatment of adults with moderate to severe psoriasis. The drug is the only IL-17A antagonist approved for all three indications. learn more
Age at onset influences psoriatic arthritis disease factors
February 10th 2016The age at which a patient first develops indications of psoriatic arthritis may influence various disease factors. Early onset appears to be associated with more extensive disease; while late onset is associated with several metabolic complications. Here’s what this means.
Small scaly papules in a follicular configuration
February 9th 2016A 67-year-old man visited his dermatologist complaining of a rash that had developed over the past two weeks that caused intense pruritus. The small scaly papules were in a follicular configuration on his back. His wife told him the rash had developed a few blisters. He noticed it was worse after his daily workout when he worked up a sweat.
What looks promising in the pipeline for psoriasis
February 8th 2016As research advances understanding of psoriasis, drug development evolves to address various pathways to disease. A number of possibilities, now in clinical trials, appear safe, effective and promising with improved long-term clearance rates.
Where to get the latest on Zika virus
February 2nd 2016As you flip through the various TV channels, it’s the top headline scrolling across your TV screen on every news station, The Zika virus. This mosquito-born virus could soon make its way to the United States and is raising major concerns for pregnant women and physicians. Get the information you need to care for your patients.
Faster response to antibiotic therapy failure needed
February 1st 2016Study demonstrates current antibiotic use for acne therapy far surpasses guideline recommendations and calls for dermatologists to decrease extended courses of antibiotics through early recognition of failure and guiding patients to alternative therapies.
Clarifying ingenol labeling changes
February 1st 2016Concerns have been raised over an FDA Drug Safety Communication about spontaneously submitted adverse reactions in patients using this topical treatment for actinic keratosis as well as labeling changes that were implemented because of those reports. One expert offers perspective.